NASDAQ:XOMAO XOMA (XOMAO) Stock Price, News & Analysis $25.00 0.00 (0.00%) As of 10/9/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendFinancialsNews and TrendsSEC Filings About XOMA Stock (NASDAQ:XOMAO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XOMA alerts:Sign Up Key Stats Today's Range$25.00▼$25.0050-Day Range$25.00▼$25.0052-Week Range$24.86▼$26.40VolumeN/AAverage Volume4,279 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.36%Price TargetN/AConsensus RatingN/A Company Overview XOMA Corporation is a biotechnology royalty aggregator that acquires economic interests in potential future payments from partnered pharmaceutical and biotechnology programs. Rather than operating primarily as a traditional drug developer, the company builds a portfolio of rights to milestone payments, royalties and other commercial proceeds associated with therapeutic candidates and marketed medicines. The company’s portfolio has included programs across areas such as immunology, oncology, rare diseases and infectious diseases. XOMA typically obtains these interests through licensing transactions, acquisitions or partnerships involving biotechnology companies and other life sciences organizations. The value of its business is tied to the clinical development, regulatory progress and commercial performance of the underlying programs owned or advanced by its partners. Founded in 1981, XOMA historically focused on discovering and developing antibody-based therapeutics before transitioning toward its current royalty-aggregation model. The company is headquartered in Emeryville, California, and works with biotechnology and pharmaceutical partners internationally. XOMAO represents XOMA’s Series A preferred stock, while the company’s common stock trades under the symbol XOMA.AI Generated. May Contain Errors. Read More Receive XOMAO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMAO Stock News HeadlinesLigand (LGND)-AvenCell Deal: Most of the Funding Is Tied to MilestonesSeptember 27, 2026 | finance.yahoo.comXoma secures a SEK 5m credit facilitySeptember 2, 2026 | marketscreener.comMThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO as soon as this fall. TradeSmith CEO Keith Kaplan says chasing the next hot IPO isn't necessary. His AI-driven system, built on a platform pioneered by Google, ranks every stock in the S&P 500 and narrows the list to just five names to hold each month. Backtests show the Top Five Stocks outperformed the S&P 500 by 4x in August alone.October 10 at 1:00 AM | TradeSmith (Ad)XOMA Stock (NASDAQ:XOMAO), Earnings Estimates, EPS, and RevenueMay 27, 2026 | benzinga.comLigand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 millionApril 27, 2026 | msn.comLigand Pharmaceuticals buying Xoma Royalty for $739 millionApril 27, 2026 | finance.yahoo.comLigand Pharmaceuticals: Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorApril 27, 2026 | finanznachrichten.deLigand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 millionApril 27, 2026 | msn.comSee More Headlines XOMAO Stock Analysis - Frequently Asked Questions How have XOMAO shares performed this year? XOMA's stock was trading at $25.56 on January 1st, 2026. Since then, XOMAO stock has decreased by 2.2% and is now trading at $25.00. How do I buy shares of XOMA? Shares of XOMAO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 7/14 Dividend7/02/2026Ex-Dividend for 7/14 Dividend7/02/2026Dividend Payable7/14/2026Today10/10/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (33m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 XOMAO's financial health is in the Green zone, according to TradeSmith. XOMAO has been in this zone for over 33 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMAO CIK791908 Webwww.xoma.com Phone510-204-7200FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$7.65 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:XOMAO) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XOMAO Stock Alerts